Last reviewed · How we verify
Prednisolone Acetate 0.12%
Prednisolone acetate is a corticosteroid that suppresses inflammatory and immune responses by binding to glucocorticoid receptors and inhibiting pro-inflammatory cytokine production.
Prednisolone acetate is a corticosteroid that suppresses inflammatory and immune responses by binding to glucocorticoid receptors and inhibiting pro-inflammatory cytokine production. Used for Inflammation and pain following ocular surgery, Allergic conjunctivitis, Anterior uveitis.
At a glance
| Generic name | Prednisolone Acetate 0.12% |
|---|---|
| Also known as | Pred Mild (Allergan) |
| Sponsor | ORA, Inc. |
| Drug class | Corticosteroid |
| Target | Glucocorticoid receptor |
| Modality | Small molecule |
| Therapeutic area | Ophthalmology |
| Phase | FDA-approved |
Mechanism of action
As a topical ophthalmic corticosteroid, prednisolone acetate reduces inflammation, edema, and immune cell infiltration in the eye. It works by translocating to the nucleus and modulating gene expression of inflammatory mediators. The 0.12% formulation is a lower-strength preparation used for mild to moderate ocular inflammation.
Approved indications
- Inflammation and pain following ocular surgery
- Allergic conjunctivitis
- Anterior uveitis
- Corneal injury from chemical, radiation, or thermal burns
Common side effects
- Elevated intraocular pressure
- Posterior subcapsular cataract formation
- Secondary ocular infection
- Ocular irritation or discomfort
Key clinical trials
- CD34+ (Malignant) Stem Cell Selection for Patients Receiving Allogenic Stem Cell Transplant (PHASE1, PHASE2)
- Difluprednate vs. a Prednisolone Acetate - Phenylephrine on Post-operative Inflammation Following Cataract Surgery. (PHASE4)
- Evaluation of the Efficacy of Topical Ophthalmic Steroids in a Modified Conjunctival Allergen Challenge (CAC) Model (PHASE4)
- Steroid Withdrawal in Pediatric Renal Transplant: Impact on Growth, Bone Metabolism and Acute Rejection (PHASE3)
- Evaluation of Efficacy of Coadministration of FOV1101-00 and Prednisolone Acetate in Patients With Mild Ongoing Ocular Allergic Inflammation (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Prednisolone Acetate 0.12% CI brief — competitive landscape report
- Prednisolone Acetate 0.12% updates RSS · CI watch RSS
- ORA, Inc. portfolio CI